Progen Update On Phase 3 Clinical Program For PI-88 In Liver Cancer
Progen Update On Phase 3 Clinical Program For PI-88 In Liver Cancer
|
Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) announced that in light of the recent Fast Track designation awarded to PI-88 for the prevention of tumour recurrence following curative resection of primary liver cancer and in order to commence the Phase 3 program as rapidly as possible, the Company will no longer continue with the Special Protocol Assessment process. [click link for full article] |
read more...
News entry number 3003 added on Nov 4, 2007 in the Health category.
Comenteaza
Other News in the Health category
Categorie:
Categorie:
Categorie:
Categorie:
Categorie:
Related Links
- Irish uses all 3 QBs in 33-3 loss
- The DNA Age: Cancer Free at 33, but Weighing a Mastectomy
- Clavis Pharma ASA To Present Phase I Clinical Results From ELACYT In Patients With Cancers Of The Bl
- Mets 3, Braves 2: Successful Audition by Pérez for Postseason Rotation
- Memory Pharmaceuticals Announces Positive Phase 2a Results For MEM 3454 In Alzheimer's Disease
- Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial For Psoriasis
- No. 3 Missouri 36, No. 2 Kansas 28: Tigers Hand Kansas First Loss
- Australian Scientist to Lead $3 Billion Stem Cell Research Program in California
- Martínez Gets 3,000th Strikeout in Win
News Categories
745
523
480
347
1011
693
280
973
Top 10 News
- Texas Woman Claims to Have Found Mythical 'Chupacabra'
- Google Starts Hosting News on Website
- Wireless technology hits security budgets
- Google forced to push image in China
- Western School Board limits digital devices
- 'Spooky' science points to quantum internet
- Nuñez, gov. gamble on healthcare overhaul
- Ho-hum, the guest's another candidate
- Study Focuses On Cancer Risk In Biologic Treatment For Rheumatoid Arthritis
- Microsoft purchase of RIM nice to consider, but unlikely
Statistics
News:
News Categories:
News Read:
News Categories:
News Read:
5052
8
610
8
610